Business Wire

Save Money While Seeking the Sun: Cost Effective Winter Stays in Egypt

25.1.2023 11:00:00 EET | Business Wire | Press release

Share

Spending the winter season in a warm place has always been popular, whether you’re a digital nomad or a pensioner. But, the rising cost of living over the past year could cause many to reconsider whether, or how, they travel.

While Egypt has long been on travelers’ radar, thanks to its low-cost of living, it has now become a popular long-stay winter destination. In fact, a one month stay in a luxurious three or four-star-hotel can cost less than living in the Western European countries for the same amount of time.

Research collated by the Egyptian Government from a variety of tour operators shows a four-week winter sun stay costs, on average, €1 218 per couple. This includes 160€ per person for a return flight, 25€ per couple for a double room in a four-star hotel and 8€ per person for a three-course dinner at a local restaurant.

In comparison, the average monthly cost of a two-person household for gas, energy, food and beverages is 1 396€ in Italy, 1 509€ in France and 1 601€ in Germany during the winter.

The Egyptian Government is currently promoting and facilitating month long stays at a wide variety of hotels.

Amr El-Kady, CEO of Egyptian Tourism Authority, said: “Egypt is always happy to welcome travelers from Europe. We are doing our best to make the stay as effortless and affordable as possible. This winter season, we invite you to spend the cold months under the kind Egyptian sun, saving the budget and filling life with fantastic new experiences”.

What does Egypt have to offer? Plenty.

From Cairo to Luxor, from the beguiling desert to the lush delta of the Nile, Egypt is a traveler's dream. Whether diving into the rich underwater world of the Red Sea, sailing on the Nile towards the sunset or tracing the secrets of the ancient Egyptians in stunning temple complexes, the land of the pharaohs has something to offer to every visitor.

Among the most famous destinations is the capital Cairo, where you can immerse yourself in all eras of Egyptian history in the Egyptian Museum, and visit the famous Pyramids of Giza with the impressive Sphinx. Another highlight is the city of Luxor, which offers some spectacular wonders, that include the Valley of the Kings, the Temple of Karnak and the legendary Luxor Temple, which is one of the absolute must-sees on any trip and continues to enchant with ancient stories.

If you prefer active and adventurous activities, you don't have to look far. Egypt is not only a diver's paradise, but also offers desert excursions, Nile cruises and breathtaking landscapes such as the Colored Canyon National Park on the Sinai Peninsula. While ecotourism is becoming increasingly popular in the country and even spiritual tours are offered, Egypt is also known for particularly high-quality spa treatments.

A variety of flight connections ensure a pleasant way to get there. There are direct flights to resorts of Egypt from almost every major European city.

Find out what else Egypt has to offer on Egypt travel - Home (experienceegypt.eg)

- ENDS –

Destination images can be downloaded here

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

External Press office
Philipp Koneev, Senior Account Manager, MC Group
p.koneev@mcgroup.com
+49 30 65000‑540

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye